Invesco Ltd. Pliant Therapeutics, Inc. Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 46,332 shares of PLRX stock, worth $505,482. This represents 0.0% of its overall portfolio holdings.

Number of Shares

46,332

Previous 47,155 1.75%

Holding current value

$505,482

Previous $506,000 2.57%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$10.52 - $14.35 $8,657 - $11,810	-823 Reduced 1.75%	46,332 $519,000
Q2 2024 Aug 13, 2024	SELL	$10.58 - $15.61 $6,633 - $9,787	-627 Reduced 1.31%	47,155 $506,000
Q1 2024 May 14, 2024	BUY	$14.14 - $19.59 $286,448 - $396,854	20,258 Added 73.6%	47,782 $711,000
Q4 2023 Feb 12, 2024	SELL	$12.85 - $19.15 $147,145 - $219,286	-11,451 Reduced 29.38%	27,524 $498,000
Q3 2023 Nov 13, 2023	BUY	$14.58 - $20.15 $116,362 - $160,817	7,981 Added 25.75%	38,975 $675,000
Q2 2023 Aug 11, 2023	BUY	$18.12 - $30.56 $561,611 - $947,176	30,994 New	30,994 $561,000
Q3 2022 Nov 14, 2022	BUY	$7.67 - $24.23 $2.09 Million - $6.61 Million	272,667 New	272,667 $5.7 Million
Q2 2022 Aug 15, 2022	SELL	$4.11 - $8.75 $41,922 - $89,250	-10,200 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$7.01 - $14.1 $1,324 - $2,664	189 Added 1.89%	10,200 $72,000
Q4 2021 Feb 14, 2022	SELL	$12.27 - $18.26 $14,601 - $21,729	-1,190 Reduced 10.62%	10,011 $134,000
Q3 2021 Nov 15, 2021	BUY	$16.48 - $28.98 $27,983 - $49,208	1,698 Added 17.87%	11,201 $189,000
Q2 2021 Aug 17, 2021	BUY	$28.05 - $37.69 $266,559 - $358,168	9,503 New	9,503 $276,000

Others Institutions Holding PLRX

# of Institutions

169

Shares Held

63.2M

Call Options Held

245K

Put Options Held

373K

View Full List

About PLIANT THERAPEUTICS, INC.

Ticker PLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,682,000
Market Cap $531M
Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...

More about PLRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account